Pharmaceuticals, Biotechnology and Life Sciences
WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage…
Reference is made to the stock exchange announcement by Ultimovacs ASA (the “Company”) on 17 December 2024 regarding the agreement…
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON AB8939, A NOVEL MICROTUBULE DESTABILIZER ESCAPING MULTIDRUG RESISTANCE AND STEM CELL TARGETED…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR…
Tuesday, December 17, 2024 at 8:00 am ESTREDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”)…
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in…
Italian clinical-stage oncology company BetaGlue Therapeutics, developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose, announced Monday that the ENEA-Tech and Biomedical Foundation (“ENEA-Tech”) has invested €6m bringing the total raised in the current funding round to €24m.
Novo Nordisk announced Monday it plans to invest 8.5 billion Danish kroner (€1.14B) to establish a completely new production facility in Odense, Denmark.